| A neo-Schumpeterian model of health services innovation P Windrum, M García-Goñi Research policy 37 (4), 649-672, 2008 | 441 | 2008 |
| Prevalence and costs of multimorbidity by deprivation levels in the basque country: a population based study using health administrative databases JF Orueta, A García-Álvarez, M García-Goñi, F Paolucci, R Nuño-Solinís PloS one 9 (2), e89787, 2014 | 104 | 2014 |
| Innovation and motivation in public health professionals M García-Goñi, A Maroto, L Rubalcaba Health Policy 84 (2-3), 344-358, 2007 | 98 | 2007 |
| The first months of the COVID-19 pandemic in Spain J Henriquez, E Gonzalo-Almorox, M Garcia-Goñi, F Paolucci Health Policy and Technology 9 (4), 560-574, 2020 | 84 | 2020 |
| Pathways towards chronic care-focused healthcare systems: evidence from Spain M García-Goñi, C Hernández-Quevedo, R Nuño-Solinís, F Paolucci Health Policy 108 (2-3), 236-245, 2012 | 71 | 2012 |
| La medida de la morbilidad atendida en una organización sanitaria integrada JM Inoriza, J Coderch, M Carreras, L Vall-llosera, M García-Goñi, ... Gaceta Sanitaria 23, 29-37, 2009 | 68 | 2009 |
| Socio-economic impact of antiretroviral treatment in HIV patients. An economic review of cost savings after introduction of HAART T Gonzalo, M Garcia Goni, MÁ Muñoz-Fernández AiDS Rev 11 (2), 79-90, 2009 | 55 | 2009 |
| Addressing multimorbidity to improve healthcare and economic sustainability F Colombo, M García-Goñi, C Schwierz Journal of comorbidity 6 (1), 21-27, 2016 | 44 | 2016 |
| The impact of patient-centered versus didactic education programs in chronic patients by severity: the case of type 2 diabetes mellitus P Windrum, M García-Goñi, H Coad Value in health 19 (4), 353-362, 2016 | 41 | 2016 |
| Predictability of drug expenditures: an application using morbidity data M García‐Goñi, P Ibern Health Economics 17 (1), 119-126, 2008 | 40 | 2008 |
| Estimates of patient costs related with population morbidity: can indirect costs affect the results? M Carreras, M García-Goñi, P Ibern, J Coderch, L Vall-Llosera, JM Inoriza The European Journal of Health Economics 12 (4), 289-295, 2011 | 37 | 2011 |
| Hybrid risk adjustment for pharmaceutical benefits M García-Goñi, P Ibern, JM Inoriza The European Journal of Health Economics 10 (3), 299-308, 2009 | 35 | 2009 |
| Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries P Baji, M García-Goñi, L Gulácsi, E Mentzakis, F Paolucci The European Journal of Health Economics 17 (7), 791-799, 2016 | 26 | 2016 |
| The evolution of obesity in Spain M García-Goñi, C Hernández-Quevedo Eurohealth 18 (1), 22-25, 2012 | 22 | 2012 |
| Ajuste de riesgos en los mercados sanitarios M García Goñi Integración asistencial: fundamentos, experiencias y vías de avance …, 2006 | 21 | 2006 |
| Specializing nurses as an indirect education program for stoma patients M García-Goñi International journal of environmental research and public health 16 (13), 2272, 2019 | 20 | 2019 |
| Budget impact analysis of biosimilar products in Spain in the period 2009–2019 M García-Goñi, I Río-Álvarez, D Carcedo, A Villacampa Pharmaceuticals 14 (4), 348, 2021 | 17 | 2021 |
| Rationalizing pharmaceutical spending M García-Goñi International Monetary Fund, 2022 | 16 | 2022 |
| Measurement of morbidity attended in an integrated health care organization JM Inoriza, J Coderch, M Carreras, L Vall-Llosera, M García-Goñi, ... Gaceta Sanitaria 23 (1), 29-37, 2009 | 14 | 2009 |
| Mental illness inequalities by multimorbidity, use of health resources and socio-economic status in an aging society M García-Goñi, AP Stoyanova, R Nuño-Solinís International Journal of Environmental Research and Public Health 18 (2), 458, 2021 | 13 | 2021 |
